OncoTherapy Science, Inc.
18.00
JPY
0.00
(0.00%)
ISIN
JP3202150003
Return %
Stock
S&P 500
1Y
-25.00
14.20
3Y
-37.93
81.12
5Y
-77.78
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Junichi Shimada
- Full Time Employees
- 46
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 1-2 Higashida-cho Kawasaki KN Japan 210-0005
- IPO Date
- Dec 8, 2003
- Website
- oncotherapy.co.jp
- Similar Companies
- Business
- OncoTherapy Science, Inc. (4564.T) is a Japan-based biopharmaceutical company focused on the research, development, and commercialization of oncology therapeutics through targeted approaches to cancer-related genes and proteins. Founded on April 6, 2001, and headquartered in Kawasaki-ku, Kawasaki City, Kanagawa Prefecture, the company operates primarily in Japan with clinical activities extending to the United States, Australia, Europe, Singapore, and South Korea; it maintains a consolidated subsidiary, Cancer Precision Medicine, Inc., specializing in cancer genome analysis, liquid biopsy, neoantigen prediction, TCR/BCR repertoire analysis, and immunotherapy development. Core products and services encompass small-molecule drugs including OTS167, a first-in-class MELK inhibitor in Phase I/II for breast cancer (including triple-negative breast cancer), acute myeloid leukemia, and demonstrating antitumor activity in lung, prostate, pancreatic, and other models, alongside preclinical candidates targeting TOPK and SUV39H2; cancer peptide vaccines such as S-588410 (licensed to Shionogi & Co., Ltd., post-Phase III for esophageal cancer with subgroup survival benefits, plus Phase II for bladder cancer), S-588210 (Phase I/II for solid tumors and head/neck cancer), S-488210 (Phase I/II for head/neck cancer), and OTSGC-A24 (Phase I combination with immune checkpoint inhibitors for gastric cancer); antibody drugs like OTSA101 (Phase I completed for synovial sarcoma, with radioisotope conjugate safety confirmed) and anti-amyloid β peptide antibodies for licensing; and precision medicine services via its subsidiary covering whole genome sequencing, neoantigen dendritic cell therapy, and immune response analysis for cancer patients. Recent developments include the merger of Immunas Pharma, Inc. into the parent company in March 2024, completion of Shionogi's Phase III trial for S-588410 in esophageal cancer (2024, prompting ongoing strategy discussions), enrollment completion and positive safety data for OTS167 Phase I/II in AML and OTSA101 Phase I in synovial sarcoma, favorable bioavailability results from OTS167 healthy volunteer study in Australia, and transition to the Tokyo Stock Exchange Growth Market in April 2022 followed by headquarters relocation to current Kawasaki-ku site in January 2023.